How Does Brooklyn Immunotherapeutics Inc (BTX) Stock Rank on Wall Street Wednesday?

Wednesday, April 27, 2022 03:11 PM | InvestorsObserver Analysts

Mentioned in this article

How Does Brooklyn Immunotherapeutics Inc (BTX) Stock Rank on Wall Street Wednesday?

InvestorsObserver is giving Brooklyn Immunotherapeutics Inc (BTX) an Analyst Rating Rank of 72, meaning BTX is ranked higher by analysts than 72% of stocks. The average price target for BTX is $7 and analyst’s rate the stock as a Strong Buy.

Wall Street analysts are rating BTX a Strong Buy today. Find out what this means to you and get the rest of the rankings on BTX!

See Full BTX Report

Why are Analyst Ratings Important?

Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve. InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.

What's Happening With Brooklyn Immunotherapeutics Inc Stock Today?

Brooklyn Immunotherapeutics Inc (BTX) stock has fallen -1.32% while the S&P 500 has gained 0.39% as of 3:09 PM on Wednesday, Apr 27. BTX is down -$0.01 from the previous closing price of $1.14 on volume of 324,695 shares. Over the past year the S&P 500 has risen 0.12% while BTX is down -95.46%. BTX lost -$1.68 per share the over the last 12 months. Click Here to get the full Stock Report for Brooklyn Immunotherapeutics Inc stock.